FILE – In this Thursday, April 8, 2021 file photo, the Johnson & Johnson COVID-19 vaccine sits on a table at a pop up vaccinations site the Albanian Islamic Cultural Center, in the Staten Island borough of New York. The U.S. is recommending a “pause” in administration of the single-dose Johnson & Johnson COVID-19 vaccine to investigate reports of potentially dangerous blood clots. (AP Photo/Mary Altaffer, File)
UCSF confirms they are treating a man who developed rare blood clots after receiving the Johnson & Johnson vaccine.
According to UCSF, the patient in his 30s is believed to be the first man in the United States with VITT syndrome – vaccine-induced thrombotic thrombocytopenia. Doctors at UCSF say the man is responding well to treatment and should be released soon, according to the SF Chronicle.
“I would expect him to leave the hospital in the next few days,” Dr. Andrew Leavitt, a hematologist who oversaw his care at UCSF, said in an interview Sunday night. “I saw him today, and he was doing beautifully. When I saw him he was in good spirits chatting with his dad.”
The news comes after the Food and Drug Administration recommended the Johnson & Johnson vaccine can begin again after a brief pause. The US FDA recommended a ‘pause’ for J&J vaccine over 6 reported blood clots two weeks ago.
As of 4/12, 6.8m+ doses of the J&J vaccine have been administered in the U.S. CDC & FDA are reviewing data involving 6 reported U.S. cases of a rare & severe type of blood clot in individuals after receiving the vaccine. Right now, these adverse events appear to be extremely rare
— U.S. FDA (@US_FDA) April 13, 2021
Last week, the FDA said Johnson and Johnson vaccine could resume.
Following a thorough safety review, the FDA and @CDCgov have determined that the recommended pause regarding the use of the Johnson & Johnson (Janssen) #COVID19 Vaccine in the U.S. should be lifted and use of the vaccine should resume. https://t.co/QSuse0jyas pic.twitter.com/cdIH1yHa8s
— U.S. FDA (@US_FDA) April 23, 2021
“The two agencies have determined the available data show that the vaccine’s known and potential benefits outweigh its known and potential risks in individuals 18 years of age and older.” US FDA continue to tweet, “The surveillance systems in place to monitor the safety of #COVID19 vaccines authorized for emergency use are working, as demonstrated by both agencies’ quick work to identify and investigate these rare, but serious adverse events.”
“You are, as a woman, less likely to get the blood clot problem than to get struck by lightning next year,” said Dr. Francis Collins, director of the National Institutes of Health.
“The CDC did a great job with the pause,” Dr. Andrew Leavitt said. “Absolutely this should not preclude people from getting vaccinated.”